Mylan has signed a settlement and license agreements with Shionogi and CIMA Labs regarding Prednisolone sodium phosphate orally disintegrating tablets (ODT), known generically as Orapred ODT.
Mylan said that following the settlement agreement, it is expected to get the rights to market Prednisolone sodium phosphate ODT product in the US on 1 April 2014, or earlier under certain circumstances.
Shionogi's Orapred ODT, which is available in 10 mg, 15 mg and 30 mg dosage forms, is used for the treatment of certain pulmonary diseases such as asthma.
In addition, the product controls certain severe or incapacitating allergic conditions such as atopic dermatitis, and seasonal and perennial allergic rhinitis.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/mylan-in-patent-settlement-with-shionogi-cima-for-prednisolone-odt-111012
